Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells

Objective: Despite the promise of PARP inhibitors (PARPi) for treating BRCA1/2 mutated ovarian cancer (OC), drug resistance invariably develops. We hypothesized rationale drug combinations, targeting key molecules in DNA repair pathways and the cell cycle may be synergistic and overcome acquired PAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgess, Brian T., Anderson, Abigail M., McCorkle, J. Robert, Wu, Jianrong, Ueland, Frederick R., Kolesar, Jill M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168282/
https://www.ncbi.nlm.nih.gov/pubmed/32098452
http://dx.doi.org/10.3390/diagnostics10020121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168282/
https://www.ncbi.nlm.nih.gov/pubmed/32098452
http://dx.doi.org/10.3390/diagnostics10020121

Ejemplares similares